[an error occurred while processing this directive] | [an error occurred while processing this directive]
Role of intensity-modulated radiation therapy combined with chemotherapy in patients with stage T1-2N1M0 nasopharyngeal carcinoma:a retrospective study
Li Peijing1,2, Jin Ting2, Chen Yuanyuan3, Chen Ming1,2, Tian Ye1
1Department of Radiotherapy&Oncology, Second Affiliated Hospital of Soochow University, Institute of Radiotherapy&Oncology, Soochow University; Suzhou Key Laboratory for Radiation Oncology, Suzhou 215004, China; 2Department of Radiotherapy, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital); Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 321400, China; 3Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, ChinaLi Peijing and Jin Ting contributed equally to this article
AbstractObjective To evaluate the efficacy of intensity-modulated radiation therapy (IMRT) combined with chemotherapy for treating patients with T1-2N1M0 nasopharyngeal carcinoma (NPC). Methods 343 patients diagnosed with T1-2N1M0 NPC in Zhejiang Cancer Hospital and Sun Yat-sen University Cancer Center from January 2008 to December 2016 were recruited in this study. All patients received IMRT and divided into the radiotherapy (RT) and chemoradiotherapy (CRT) groups. Patients in the CRT group were further assigned into the concurrent chemoradiotherapy (CCRT), induction chemotherapy+ CCRT (IC+CCRT) and CCRT+ adjuvant chemotherapy (AC) groups. Locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) were estimated by Kaplan-Meier method. Multivariate prognostic analysis was performed by Cox models. Results The median follow-up time for surviving patients (303/343) was 91(range:49-138) months. The 5-year OS, CSS, PFS, LRFFS, and DMFS rates in the CRT group were not superior to those of the RT group (93.7%:93.9%,93.7%:93.9%,89.0%:87.7%,93.8%:92.8%,93.8%:91.2%, all P>0.05). No significant difference was found in treatment outcomes of patients with T1N1 or T2N1 NPC between two groups (all P>0.05). In multivariable analyses, only age was an independent prognostic factor for OS, PFS, CSS and DMFS, and negative correlation was found between them. No survival benefits were achieved in the CCRT, IC+CCRT, CCRT+AC and RT groups, and no significant differences were found in clinical efficacy among the three combined (all P>0.05). Conclusions IMRT alone yields comparable clinical efficacy to CRT in treating patients with T1-2N1M0 NPC. However, whether CT can be eliminated in the T1-2N1M0 population still needs further confirmation by prospective, randomized and controlled clinical trials.
Corresponding Authors:
Tian Ye, Email:dryetian@126.com
Cite this article:
Li Peijing,Jin Ting,Chen Yuanyuan et al. Role of intensity-modulated radiation therapy combined with chemotherapy in patients with stage T1-2N1M0 nasopharyngeal carcinoma:a retrospective study[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1227-1232.
Li Peijing,Jin Ting,Chen Yuanyuan et al. Role of intensity-modulated radiation therapy combined with chemotherapy in patients with stage T1-2N1M0 nasopharyngeal carcinoma:a retrospective study[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1227-1232.
[1] Pfister DG, Spencer S, Adelstein D, et al. NCCN clinical practice guidelines in oncology:head and neck cancers version1[EB/OL][2021-04-01] https://www.nccn.org/patients. [2] Chen J, Dassarath M, Yin Z, et al. Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma:a review of new avenues in its management[J]. Radiat Oncol, 2011, 6:128. DOI:10.1186/1748-717X-6-128. [3] Chen KH, Zhu XD, Li L, et al.comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage Ⅱ nasopharyngeal carcinoma[J]. Oncotarget, 2016, 7(42):69041-69050. DOI:10.18632/oncotarget.11978. [4] Su Z, Mao YP, Tang J, et al. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma treated with IMRT:a retrospective study[J]. Tumour Biol, 2016, 37(4):4429-4438. DOI:10.1007/s13277-015-4266-5. [5] Chen YP, Ismaila N, Chua M, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage Ⅱ-IVA nasopharyngeal carcinoma:CSCO and ASCO guideline[J]. J Clin Oncol, 2021, 39(7):840-859. DOI:10.1200/JCO.20.03237. [6] Luo S, Zhao L, Wang J, et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO Ⅱ histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China[J]. Head Neck, 2014, 36(6):841-847. DOI:10.1002/hed.23386. [7] Huang X, Chen X, Zhao C, et al. Adding Concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage Ⅱ nasopharyngeal carcinoma:a phase 2 multicenter clinical trial[J]. Front Oncol, 2020, 10:1314. DOI:10.3389/fonc.2020.01314. [8] Xiao WW, Han F, Lu TX, et al. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 74(4):1070-1076. DOI:10.1016/j.ijrobp.2008.09.008. [9] Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma:an analysis of survival and failure patterns[J]. Head Neck, 2005, 27(7):555-565. DOI:10.1002/hed.20189. [10] Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma[J]. J Clin Oncol, 2000, 18(10):2040-2045. DOI:10.1200/JCO.2000.18.10.2040. [11] Chua DT, Ma J, Sham JS, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma:Subgroup analysis of two Phase Ⅲ trials[J]. Int J Radiat Oncol Biol Phys, 2006, 65(5):1300-1306. DOI:10.1016/j.ijrobp.2006.02.016. [12] Li XY, Chen QY, Sun XS, et al. Ten-year outcomes of survival and toxicity for a phase Ⅲ randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma[J]. Eur J Cancer, 2019, 110:24-31. DOI:10.1016/j.ejca.2018.10.020. [13] Xu T, Hu C, Wang X, et al. Role of chemoradiotherapy in intermediate prognosis nasopharyngeal carcinoma[J]. Oral Oncol, 2011, 47(5):408-413. DOI:10.1016/j.oraloncology.2011.03.008. [14] Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy:a 10-year experience with a large cohort and long follow-up[J]. Eur J Cancer, 2015, 51(17):2587-2595. DOI:10.1016/j.ejca.2015.08.006. [15] Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J]. Int J Radiat Oncol Biol Phys, 2011, 80(3):661-668. DOI:10.1016/j.ijrobp.2010.03.024. [16] Sun XS, Liu DH, Liu SL, et al. Patterns of failure and survival trends in 3,808 patients with stage Ⅱ nasopharyngeal carcinoma diagnosed from 1990 to 2012:a large-scale retrospective cohort study[J]. Cancer Res Treat, 2019, 51(4):1449-1463. DOI:10.4143/crt.2018.688. [17] Chua DT, Sham JS, Kwong DL, et al. Treatment outcome after radiotherapy alone for patients with stage Ⅰ-Ⅱ nasopharyngeal carcinoma[J]. Cancer, 2003, 98(1):74-80. DOI:10.1002/cncr.11485.
2021, Vol. 30 
